Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).

Literature DB >> 19806596

Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).

Carrie Printz.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19806596 DOI： 10.1002/cncr.24673

Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.860

Keyword Cloud
Cited

× No keyword cloud information.

26 in total

1. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy.

Authors: Yusuke Yamamoto; Hisashi Ikoma; Ryo Morimura; Hirotaka Konishi; Yasutoshi Murayama; Shuhei Komatsu; Atsushi Shiozaki; Yoshiaki Kuriu; Takeshi Kubota; Masayoshi Nakanishi; Daisuke Ichikawa; Hitoshi Fujiwara; Kazuma Okamoto; Chouhei Sakakura; Toshiya Ochiai; Eigo Otsuji
Journal: World J Gastroenterol Date: 2015-01-28 Impact factor: 5.742

Review 2. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors: Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal: Curr Cancer Drug Targets Date: 2012-11-01 Impact factor: 3.428

Review 3. Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

Authors: Gar-Yang Chau
Journal: World J Gastroenterol Date: 2014-09-21 Impact factor: 5.742

4. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.

Authors: Wei Zhang; Gang Zhao; Kai Wei; Qingxiang Zhang; Weiwei Ma; Qiang Wu; Ti Zhang; Dalu Kong; Qiang Li; Tianqiang Song
Journal: Med Oncol Date: 2015-03-07 Impact factor: 3.064

5. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.

Authors: Hiroki Nishikawa; Norihiro Nishijima; Hirayuki Enomoto; Azusa Sakamoto; Akihiro Nasu; Hideyuki Komekado; Takashi Nishimura; Ryuichi Kita; Toru Kimura; Hiroko Iijima; Shuhei Nishiguchi; Yukio Osaki
Journal: Oncol Lett Date: 2017-05-31 Impact factor: 2.967

Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).

1. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy.

Review 2. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Review 3. Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

4. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.

5. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.

Review 6. Recent advances in multidisciplinary management of hepatocellular carcinoma.

Review 7. Current management of hepatocellular carcinoma.

Review 8. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.

9. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient.

10. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.